ACGN — Aceragen Income Statement
0.000.00%
Last trade - 00:00
HealthcareSpeculativeMicro Cap
- $3.20m
- $1.08m
- $4.86m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.662 | 1.45 | 0 | 0 | 4.86 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 61.6 | 47.5 | 36.7 | 27.7 | 32.7 |
Operating Profit | -61 | -46.1 | -36.7 | -27.7 | -27.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -59.9 | -56.5 | -113 | 98.1 | -29.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -59.9 | -56.5 | -113 | 98.1 | -23.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -59.9 | -56.5 | -113 | 98.1 | -23.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -59.9 | -84.6 | -113 | 96.9 | -23.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -35.5 | -50.3 | -56.6 | 33.3 | -5.52 |